Seven Cancer Centers in United States Open for Enrollment in Amended Trial
NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Delcath
Systems, Inc. (OTCQB: DCTH), please note the first sentence of the first paragraph should read: "Delcath Systems, Inc. (OTCQB:
DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancer centers of the liver, announces
the addition of six major cancer centers in the United States that have adopted the amended trial protocol for the company’s
registration trial in ocular melanoma liver metastases." Complete corrected text follows.
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and
metastatic cancers of the liver, announces the addition of six major cancer centers in the United States that have adopted the
amended trial protocol for the company’s registration trial in ocular melanoma liver metastases. These centers join Stanford
Medical Center in initiating enrollment in the amended trial, giving the company wide geographic coverage in the United States.
Joining Stanford Medical Center are:
- Moffitt Cancer Center - Tampa, FL Center 1
- Thomas Jefferson University Hospital – Philadelphia, PA
- Emory University Hospital, Atlanta, GA
- Methodist University Hospital, Memphis, TN
- The University of Arizona Medical Center, Tucson, AZ
- Ohio State University Cancer Care Center – Columbus, OH
The trial, A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and
Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma (The FOCUS Trial), is enrolling
a minimum of 80 patients with ocular melanoma metastatic to the liver. The Company expects approximately 30 leading cancer centers
in the U.S. and Europe to participate in the amended FOCUS Trial.
“Our team has been working diligently with participating medical centers to expedite the adoption of the new
single-arm protocol,” said Jennifer K. Simpson, PhD, MSN, CRNP, President and Chief Executive Officer of Delcath Systems. “These
additional centers provide greater geographic coverage for this trial, which will help improve patient access. We look forward to
the adoption of the amended protocol by additional centers in both the United States and Europe in the coming weeks and are working
hard to achieve our goal of completing trial enrollment by the end of the first half of 2019.”
About Delcath Systems
Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and
metastatic liver cancers. Our investigational product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic
Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure
and associated side effects. We have commenced a global Registration clinical trial for Patients with Hepatic Dominant Ocular
Melanoma (OM) called The FOCUS Trial and have initiated a global Phase 3 clinical trial for intrahepatic cholangiocarcinoma (ICC)
called The ALIGN Trial. Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the
U.S. In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery
System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.
Forward Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements
made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and
uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to: successful completion of the Company’s Rights Offering and related
transactions and the amount of gross proceeds, if any; the timing and results of the Company’s clinical trials including
without limitation the OM and ICC clinical trial programs, timely enrollment and treatment of patients in the global
Phase 3 OM and ICC clinical trials, IRB or ethics committee clearance of the Phase 3 OM and ICC Registration trial
protocols from participating sites and the timing of site activation and subject enrollment in each trial, the impact of the
presentations at major medical conferences and future clinical results consistent with the data presented, approval of Individual
Funding Requests for reimbursement of the CHEMOSAT procedure, the impact, if any of ZE reimbursement on potential CHEMOSAT
product use and sales in Germany, clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and filter
melphalan in Europe including the key markets of Germany and the UK, the Company’s ability to successfully commercialize the
Melphalan HDS/CHEMOSAT system and the potential of the Melphalan HDS/CHEMOSAT system as a treatment for patients with primary and
metastatic disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets,, approval of the
current or future Melphalan HDS/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for
various indications in the U.S. and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, the Company’s
ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and
revenue, if any, of the same, uncertainties relating to the timing and results of research and development projects, and
uncertainties regarding the Company’s ability to obtain financial and other resources for any research, development, clinical
trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the
Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of
the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events
or circumstances after the date they are made.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
